Synlogic_Logo_Blue.png
Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)
January 19, 2023 06:58 ET | Synlogic, Inc.
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that SYNB1934 was granted...
Synlogic_Logo_Blue.png
Synlogic Provides Corporate Update and Outlook for 2023
January 05, 2023 06:58 ET | Synlogic, Inc.
Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023 Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria (HCU) Cash runway expected into H2 2024 ...
Synlogic_Logo_Blue.png
Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 06:59 ET | Synlogic, Inc.
Top-line Phase 2 data for phenylketonuria (PKU) demonstrated robust plasma Phe reduction and high response rate; Phase 3 study initiation planned for H1 2023 Clinical readouts for SYNB1353 for...
Synlogic_Logo_Blue.png
Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3
October 18, 2022 06:59 ET | Synlogic, Inc.
Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of...
Synlogic_Logo_Blue.png
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria
May 24, 2022 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
July 30, 2021 - ROSEN LOGO.jpg
FIXX NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
April 26, 2022 11:24 ET | The Rosen Law Firm PA
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LONGSTANDING LAW FIRM, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
March 31, 2022 17:15 ET | The Rosen Law Firm PA
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
200309 AGT PKU Kelly Poster Final No 9
American Gene Technologies to Present at 2020 Inborn Errors of Metabolism Drug Development Summit in Boston
March 10, 2020 09:34 ET | American Gene Technologies
ROCKVILLE, Md., March 10, 2020 (GLOBE NEWSWIRE) -- American Gene Technologies (AGT), a leading gene and cell therapy company in Rockville, Maryland, is pleased to announce its Chief Science Officer C....
Rubius_Logo.jpg
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria
January 30, 2020 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference
January 13, 2020 08:00 ET | Rubius Therapeutics
RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration Rubius Manufacturing Facility Operational Nine Months Ahead of Schedule and Ready to Supply...